Old Web
English
Sign In
Acemap
>
authorDetail
>
Michelle Kneissl
Michelle Kneissl
Pfizer
Pathology
Pharmacology
Internal medicine
Medicine
Oncology
3
Papers
136
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.
2017
Journal of Clinical Oncology
Alex A. Adjei
Patricia LoRusso
Antoni Ribas
Jeffrey A. Sosman
Anna C. Pavlick
Grace K. Dy
Xiaofei Zhou
Esha Gangolli
Russell M Walker
Michelle Kneissl
Stephanie Faucette
Rachel Neuwirth
Viviana Bozon
Show All
Source
Cite
Save
Citations (6)
MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors: Phase I study.
2013
Journal of Clinical Oncology
Drew W. Rasco
Anthony J. Olszanski
Amita Patnaik
Guillermo Espino
Rachel Neuwirth
Stephanie Faucette
Michael Bargfrede
Esha Gangolli
Russell M Walker
Michelle Kneissl
Viviana Bozon
Show All
Source
Cite
Save
Citations (7)
Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab
2013
Journal of Clinical Oncology
Luis Fayad
Fritz Offner
Mitchell R. Smith
Gregor Verhoef
Peter Johnson
Jonathan L. Kaufman
Ama Rohatiner
Anjali S. Advani
James M. Foran
Georg Hess
Bertrand Coiffier
Myron S. Czuczman
Eva Giné
Simon Durrant
Michelle Kneissl
Kenneth T. Luu
Steven Y. Hua
Joseph Boni
Erik Vandendries
Nam H. Dang
Show All
Source
Cite
Save
Citations (123)
1